YOKNEAM, Israel and PLYMOUTH MEETING, PA, March 25 /CNW/ - Galil Medical,
a global cryotherapy company, today announced that Martin J. Emerson has been
appointed President and Chief Executive Officer. Galil Medical is a market
leader in cryotherapy technology for the minimally invasive treatment of
cancerous and non-cancerous tumours. Mr. Emerson is an experienced and
successful medical device industry executive, and was most recently President
and CEO of American Medical Systems (AMS). He will be replacing Chen Barir,
who will continue to serve on the Galil Medical Board of Directors.
Chen Barir commented, "Galil Medical is very pleased to have been able to
attract an executive with the leadership experience and stature of
Marty Emerson. We are confident that Marty will be able to help Galil Medical
sustain the growth that has been recorded since our December 2006
reorganisation and recapitalisation financing."
"I am very excited to be joining Galil Medical," said Mr. Emerson. "The
company has developed innovative cryotherapy solutions to treat prostate
cancer and renal tumours and has a promising product pipeline for the Women's
Health and Interventional Radiology markets. I look forward to working with
the talented team to expand the opportunities for Galil Medical's industry
leading technology around the globe."
Mr. Emerson has a strong track record of over 20 years of accomplishments
in the medical device industry, most recently as President and Chief Executive
Officer of AMS. During his tenure at AMS, he held executive roles including
Vice President and General Manager of International, Executive Vice President
of Global Sales and Marketing and Chief Operating Officer. Prior to joining
AMS, he held senior roles in the overseas operations for several
American-based companies including Baxter International and Boston Scientific.
About Galil Medical
Galil Medical develops, manufactures and markets innovative products
utilising a proprietary cryotherapy platform that incorporates powerful
freezing technology and revolutionary 17-gauge cryoablation needle design.
Galil Medical systems enable minimally invasive, targeted ablation of benign
and cancerous tumours while ensuring rapid recovery and enhanced quality of
life for patients. The Presice(TM) Cryoablation System features multi-point
thermal sensors (MTS) and advanced IceVue(TM) planning software for excellent
procedure control in treating prostate and renal cancer. The SeedNet(TM)
system provides physicians with an easy-to-use cryoablation solution to
precisely ablate tumours while protecting adjacent structures.
Galil Medical is a global medical device company with offices in Yokneam,
Israel; Plymouth Meeting, Pennsylvania; and London, shareholders include
Thomas, McNerney & Partners, The Vertical Group, Investor Growth Capital,
Elron Electronic Industries Ltd. (NASDAQ: ELRN) and RDC Rafael Development
Corporation, Ltd. For more information, please visit
For further information:
For further information: Pam Schwartz, Communications Manager, Galil
Medical, T: +972-4-909-3273, M: +972-52-625-4443, F: +972-4-959-1077,